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Abstract
Background: Optimal antibiotic dosing is key to maximising patient survival, and minimising the emergence of
bacterial resistance. Evidence-based antibiotic dosing guidelines for critically ill patients receiving RRT are currently
not available, as RRT techniques and settings vary greatly between ICUs and even individual patients. We aim to
develop a robust, evidence-based antibiotic dosing guideline for critically ill patients receiving various forms of RRT.
We further aim to observe whether therapeutic antibiotic concentrations are associated with reduced 28-day
mortality.
Methods/Design: We designed a multi-national, observational pharmacokinetic study in critically ill patients
requiring RRT. The study antibiotics will be vancomycin, linezolid, piperacillin/tazobactam and meropenem.
Pharmacokinetic sampling of each patient’s blood, RRT effluent and urine will take place during two separate
dosing intervals. In addition, a comprehensive data set, which includes the patients’ demographic and clinical
parameters, as well as modality, technique and settings of RRT, will be collected. Pharmacokinetic data will be
analysed using a population pharmacokinetic approach to identify covariates associated with changes in
pharmacokinetic parameters in critically ill patients with AKI who are undergoing RRT for the five commonly
prescribed antibiotics.
Discussion: Using the comprehensive data set collected, the pharmacokinetic profile of the five antibiotics will be
constructed, including identification of RRT and other factors indicative of the need for altered antibiotic dosing
requirements. This will enable us to develop a dosing guideline for each individual antibiotic that is likely to be
relevant to any critically ill patient with acute kidney injury receiving any of the included forms of RRT.
Trial registration: Australian New Zealand Clinical Trial Registry (ACTRN12613000241730) registered 28 February
2013
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Background
Acute kidney injury (AKI) is a common complication of
critical illness, and patients requiring renal replacement
therapy (RRT) have high hospital mortality rates [1, 2].
The cause of AKI is often multifactorial, however, sepsis
and septic shock remain the most important causes of
AKI in the critically ill, and account for over 50 % of
cases of AKI. Compared with non-septic AKI, septic
AKI is associated with greater derangements in haemo-
dynamic and laboratory parameters, greater severity of
illness, and higher need for mechanical ventilation and
vasoactive therapy [3]. Despite adjustment for covariates,
when compared with non-septic AKI, patients with sep-
tic AKI have a 50 % higher risk of death, and survivors
require a long duration of hospitalisation [4].
To maximise patient survival, early recognition of sep-
sis, and the timely application of antibiotics against the
offending pathogen(s) is required [5]. Therapeutic anti-
biotic concentrations need to be attained rapidly and then
appropriately maintained in order to maximise bacterial
killing [6–8]. Achieving therapeutic concentrations in
blood may also serve to minimise toxicity and reduce the
emergence of antibiotic resistance [9, 10]. Optimisation of
antibiotic dosing to achieve defined pharmacokinetic
(PK)/pharmacodynamic (PD; PK/PD) targets, has been
proposed as one such therapeutic approach [11, 12]. Exist-
ing antibiotic dosing regimens are designed to achieve
PK/PD targets, but assume the PK of a non-critically ill
patient, and are often poorly validated in the intensive care
unit (ICU) setting. There is a growing body of evidence
demonstrating the existence of significant changes in anti-
biotic PK in critically patients, particularly those with sep-
sis and septic shock [13–15].
When sepsis induces AKI of sufficient severity, RRT is
prescribed to remove waste solutes by convection,
known as haemofiltration (HF); diffusion, known as
haemodialysis (HD); or a combination of the two, known
as haemodiafiltration (HDF). To date, there is limited
evidence demonstrating a clinical outcome advantage for
any one form of RRT over another. Therefore, there is
significant heterogeneity in the clinician’s preference and
use of the various RRT modalities and settings. In
clinical use, HD will clear predominantly small mole-
cules (e.g. urea, creatinine and small antibiotics),
whereas HF also allows the additional clearance of much
larger molecules [16]. The application of RRT signifi-
cantly complicates antibiotic dosing with factors such as
altered protein binding and antibiotic hydrophilicity af-
fecting PK. In addition, the operational characteristics of
RRT, such as mode, filter type, blood flow rate, mem-
brane fouling, fluid replacement site and total effluent
rate, all can influence drug disposition [17].
Changes in antibiotic PK are best described in terms
of changes to the primary PK parameters, volume of
distribution (Vd) and clearance. At its most basic level,
Vd is the PK parameter that determines antibiotic load-
ing dose requirements. Hydrophilic antibiotics are usu-
ally confined to the intravascular and interstitial fluid of
tissues and have a lower Vd than more lipophilic antibi-
otics (like many quinolones). In the acute phase of crit-
ical illness, fluid resuscitation coupled with reduced
protein binding can increase the Vd. An increased Vd
has been demonstrated for penicillins [18], carbapenems
[19] and glycopeptides [20]. Where critical illness causes
a larger Vd for an antibiotic, lower antibiotic concentra-
tions will result if the dosage is not adjusted [20, 21],
supporting the need for higher doses in the acute phase
of treatment. Linezolid has a larger Vd than these other
antibiotics and this is not considered to change signifi-
cantly during critical illness [22].
The maintenance dose of antibiotic is primarily deter-
mined by clearance (CL). For antibiotics such as vanco-
mycin, piperacillin/tazobactam and meropenem, CL is
predominantly by the kidneys [23–25]. In patients with
AKI, RRT is used to substitute the loss of renal function.
The modalities that may be selected by the physician in-
clude continuous veno-venous haemofiltration (CVVHF),
continuous veno-venous haemodiafiltration (CVVHDF),
intermittent haemodialysis (IHD) and extended daily dia-
filtration (EDD-f) (EDD-f is an 8–12 per 24 h RRT treat-
ment using a modified IHD setup with the addition of an
online filtration component).
Although the effect of different RRT settings on anti-
biotic PK and blood concentrations has been previously
described in several small studies, data quantifying the
interaction of altered PK and RRT covariates remains
limited [26]. One meta-review by Jamal et al. examined
the effect of RRT settings on meropenem, piperacillin
and vancomycin CL. The authors found that the setting
most correlated with antibiotic CL was effluent flow rate
for meropenem (Spearman correlation coefficient (rs) =
0.43; p = 0.12), piperacillin (rs = 0.77; p = 0.10), and
vancomycin (rs = 0.90; p = 0.08). It could perhaps be
concluded that maintenance dosing of these antibiotics
could be guided by the effluent flow rate. However, in a
recent multicentre pharmacokinetic study, RRT dosage
(effluent rate) itself was not sufficient to be a sole pre-
dictor of trough concentrations, and a greater under-
standing of other factors that may guide dosing [27]. We
therefore propose that suboptimal antibiotic dosing
likely occurs during RRT.
Our study will address the above knowledge defi-
ciency. We aim to develop an individualised optimal
dosing algorithm that accounts for the relevant effects of
RRT modalities and patient clinical characteristics on
dosing requirements for vancomycin, linezolid,
piperacillin-tazobactam and meropenem. This know-
ledge will significantly improve antibiotic dosing by
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providing robust dosing algorithms for critically ill patients
receiving RRT. The findings will have worldwide relevance
and applicability.
Methods
The study is endorsed by the Australian and New Zealand
Intensive Care Society Clinical Trials Group (ANZICS-
CTG) and has been registered with the Australian New
Zealand Clinical Trial Registry (ACTRN12613000241730).
Design
This is a multi-national observational PK study designed
to analyse PK data using a population PK approach to
identify covariates associated with changes in PK parame-
ters for five commonly prescribed antibiotics, vancomycin,
linezolid, piperacillin/tazobactam and meropenem in crit-
ically ill patients with AKI who are undergoing RRT.
Participants and study sites
By using an international collaborative approach from
over 30 participating ICUs, the study will enrol a mini-
mum of 450 patients, who satisfy the protocol-defined
inclusion and exclusion criteria in Table 1. Patients will
be removed from the study should they meet the with-
drawal criteria listed in Table 2.
Study treatments
The number of eligible patients to be enrolled for any
individual antibiotic is 150 for patients receiving vanco-
mycin, piperacillin-tazobactam, or meropenem. For li-
nezolid, at least 50 patients will be enrolled. Each study
antibiotic will be administered and dosed according to
standard administration guidelines at each participating
centre. The study will be conducted in centres with crit-
ically ill patients receiving CVVHF, CVVHDF or EDD-f.
The RRT prescription choice will be determined by
local clinical practice. It is likely that, given the var-
iety and geographical distribution of the participating
ICUs, that most common combinations of RRT pre-
scription within each modality will be included in this
study (Table 3). The pre-study survey information
about the participating sites confirm that the study
will provide different modes of RRT, with variations
of filter surface area (>3-fold), blood flow rate (>2-
fold) and effluent flow rate (>14-fold), which together
will provide an excellent opportunity to analyse the
effect of altered RRT settings and/or modalities on
antibiotic PK.
Each site aims to recruit at least of 8–10 patients per
antibiotic. The sampling schedule (see section on PK
Samples) is defined and will be conducted for each pa-
tient on two separate dosing intervals aiming to describe
PK changes over the initial course of antibiotic therapy.
Data on patient demographics, clinical parameters, RRT
modality and operational characteristics will be collected
and analysed in line with the paper from Li et al [28]
(see Data Analysis).
Pharmacokinetic samples
Study samples will be taken from each patient when pos-
sible during one dosing interval on days 1 or 2 and then
again during another dosing interval on days 3–6 of
commencing the study antibiotics. As described in Fig. 1,
serial samples of plasma, effluent and urine (in patients
with residual urine output) will be measured to allow
construction of PK profiles.
Plasma samples
Plasma samples will be collected pre- and post filter
from designated ports within the RRT circuit at the fol-
lowing time points (0, 30, 60, 120, 180, 240, 300, 360,
420 and 480 min), where time zero (0) denotes the base-
line sampling time prior to the administration of the
study antibiotic. If drugs are administered over 12 h, a
720 min sample will also be collected. Each sample will
consist of 3 ml of blood (total blood removed per day is
60 ml; 66 ml if 12 h antibiotic dosing is used). All the
collected blood samples will be centrifuged at 3000 rpm
and separated before storage. If the filter port is not
Table 1 Inclusion and exclusion criteria
Inclusion criteria
• Age 18 years or older
• AKI requiring RRT (defined according to RIFLEa, AKINb or KDIGOc criteria)
• Expected to require RRT for at least 4 days with two (2) sampling
sechedules
• Clinical indication for IV piperacillin-tazobactam, meropenem, imipenem-
cilastatin, vancomycin or linezolid
• Presence of intra-arterial line for blood sampling if RRT filter port
sampling not possible
• Informed consent from patient or patient’s authorised representative
Exclusion criteria
• Imminent death/patient not expected to survive
• Major bleeding or blood haemoglobin concentration <70 g/L or platelets
<20 x 109/L
• Regular dosing with any of the 5 study antibiotics for greater than 36 h,
within the 7 days prior to enrolment
• Unable to obtain consent
aBellomo R et al. Crit Care 2004, 8:R204-R212 (DOI 10.1186/cc2872)
bMetha RL et al. Crit Care 2007, 11:R31 (doi:10.1186/cc5713)
cKidneyDisease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work
Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int
Suppl 2012, 2:1-138
Abbreviations: AKI acute kidney injury, RRT renal replacement therapy, RIFLE
Risk, Injury, Failure, Loss and End stage Renal Disease, AKIN Acute Kidney
Injury Network, KDIGO Kidney Disease Improving Global Outcomes,
IV intravenous
Table 2 Withdrawal criteria for SMARRT study
• Major Bleeding
• Blood haemoglobin concentration < 70 g/L
• Platelets < 20 x 109/L
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accessible for an individual time point, arterial line sam-
pling will be performed for PK analysis.
Urine samples
Urine produced during the sample collection period will
be collected (if available) and will be used to calculate
residual renal function based on the rate of creatinine
clearance. Urine samples will be measured for creatinine
concentrations by the local pathology laboratory ser-
vicing individual ICUs in line with standard procedures.
This typically involves collection of the entire volume of
urine, and creatinine clearance calculated based on the
formula:
Ucr x V = Pcr
Where,
Ucr = Urine concentration of creatinine
Pcr = Plasma concentration of creatinine
V = volume of urine per unit time
Before the residual urine is sent to the local pathology
laboratory, a one ml urine aliquot will be transferred to
a urine collection jar and labelled for storage and later
analysis of antibiotic concentration.
Effluent samples
An empty RRT effluent bag will be inserted at the start
of the dosing interval. The RRT filter will not be rou-
tinely changed at the start of sampling and the age of
the filter will be recorded. New effluent bag(s) will be
used during each sampling time period: 0–180 min,
180–240 min, 240–360 min, 360–480 min, and 480–
720 min (for 12-h dosing). An aliquot (1 ml) of effluent
will be taken from the effluent bag at the time of chan-
ging, at time points 180, 240, 360 and 480 min (and
720 min if 12 h dosing). If more than one effluent bag is
required during the effluent sampling period, then 1 ml
of effluent shall be taken from each effluent bag used, up
to a total of 5 samples (i.e. 1 ml from each of the 5 efflu-
ent bags). Throughout the sampling period, the amount
of antibiotic cleared by RRT will be determined by re-
cording the volume and concentration of effluent.
Analysis of effluent antibiotic concentration collected
at the following time points – 180, 240, 360 and
480 min (and 720 min if 12 hourly dosing) – will enable
the calculation of the sieving coefficient (Sc) or satur-
ation coefficient for dialysate (Sd) [17]. Drug clearance
by RRT will be described by calculation of Sc for
CVVHF or Sd for CVVHDF using the following
equation:
Table 3 RRT Modalities and range of setting at participating
sites






CVVHDF 0.9–1.05 180–200V 25–40
CVVHF 1.2–2.15 130–250 25–100
EDD-f 0.6–1.4 200–300 60–350
Abbreviations: RRT renal replacement therapy, CVVHDF continuous
venovenous haemodiafiltration, CVVHF continuous venovenous
haemofiltration, EDD-f extended daily dialfiltration
Fig. 1 Antibiotic Pharmacokinetic Sampling Schedule
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Sc or Sdð Þ ¼ Concentration of drug in effluentð Þ=
ðð Plasma concentration of drug½  prefilter þ
Plasma concentration of drug½  postfilterÞ=2Þ
Plasma, RRT effluent and urine will be stored at -70 °
C to -80 °C. Samples will be stored at individual sites
awaiting bulk transport by an international courier to the
Burns, Trauma, & Critical Care Research Centre, The Uni-
versity of Queensland, Brisbane, Queensland, Australia for
assay by validated chromatographic methods. An example
of the PK sampling schedule for the different dosing regi-
mens is outlined in Fig. 1.
Ethics
The study has received ethics approval from the Royal
Brisbane and Women’s Hospital Human Research Ethics
Committee (HREC/13/QRBW/1) as the lead site. All
other participating sites have also obtained individual
HREC approval.
Data collection and safety monitoring
Trained staff at each study centre will collect data and
information will be entered into a web-based clinical
trial database system (OpenClinica, LLC). Information
to be collected on the case report form is outlined in
Table 4. Personnel trained by the coordinating centre at
The University of Queensland will conduct monitoring
for the study. The first monitoring visit will be scheduled
after the participating centre has enrolled at least one
patient, with 100 % source data verification, which in-
cludes monitoring of participant consent, sample collec-
tion timesheet, adverse events, protocol deviation and
vital status at day 28 as secondary outcome. Monitoring
for subsequent patients will be performed through
source data verification of the case report form and re-
view of the OpenClinica patient profile.
Given the observational nature of the study, major ad-
verse events attributed to the study are not anticipated.
Participating centres will report all adverse events up to
day 28 in which study participation was a contributing
factor to the coordinating centre. Should an adverse
event occur, the coordinating centre will be responsible
for providing appropriate patient follow up, and ensure
all details are recorded for the study management com-
mittee to review. All serious adverse events will be re-
ported to the Royal Brisbane and Women’s Hospital
Human Research Ethics Committee and to local institu-
tional ethics committees or jurisdictional bodies.
Statistical design and analysis approach
The study aims to develop a dosing guideline of global
significance for the commonly used antibiotics in ICU
patients [29–32]. This process will be informed by a
better understanding of the distribution of relevant PK
parameters and the extent they are influenced by RRT
modalities and settings, and individual patient
characteristics.
Population pharmacokinetic analysis
The concentration-time data for each antibiotic in
plasma, RRT effluent and urine will be fitted using non-
linear mixed-effects modeling (NONMEM version 7.3,
Globomax LLC, Hanover, USA) [33]. A Digital Fortran
compiler will be used and the runs will be executed
using Wings for NONMEM (http://wfn.sourceforge.net).
Data will be analyzed using the first-order conditional
estimation method with interaction. We will attempt to
include between-subject variability and between occa-
sion variability using exponential variability models and
residual unexplained variability using a combined expo-
nential and/or additive random error model as appropri-
ate. Goodness of fit will be evaluated by visual
inspection of diagnostic scatter plots and evaluation of
the NONMEM objective function value (OFV). Statis-
tical comparison of nested models will then be under-
taken in the NONMEM program on the basis of a Chi
square (χ2) test of the difference in OFV. A decrease in
Table 4 Parameters recorded in the study case report form
Admission details
• Patient characteristics (identification number, age, sex)
• Inclusion and exclusion criteria
• Consent details
• Co-enrolment
• Date of hospital admission
• Patient’s height and weight
• Admission diagnosis
• Date of ICU admission
• APACHE II score on ICU admissionClinical details
• Site of infection
• Identification of pathogen(s) and susceptibility to study antibiotic
• SOFA score (ICU admission, and sampling occasions 1 and 2)
• Cumulative fluid balance
• Medication details (antibiotic(s), dose administered, dosing intervals)
• Clinical responseRenal Replacement Therapy
• Modality
• Filter membrane size
• Filter membrane material
• Transmembrane pressure
• Replacement fluid flow rate (pre/post dilution)
• Dialysate fluid flow rate
• Targeted hourly fluid removal rateLaboratory Investigations
• Blood sampling time
• Measured effluent volume at pre-defined collection time
• Effluent sampling time
• Residual measured urinary creatinine clearance
• Residual urine sampling time
• Haematocrit
• Liver function testsCompletion and outcome details
• Reason for discontinuation/withdrawal
• Reason for protocol deviation/violation
• Adverse events
• Vital status at ICU and hospital discharge
• 28 day survival
Abbreviations: ICU Intensive care unit, APACHE Acute Physiology and Chronic
Health Evaluation, SOFA Sequential Organ Failure Assessment Score
Roberts et al. BMC Infectious Diseases  (2016) 16:103 Page 5 of 8
the OFV of 3.84 units (P < 0.05) will be considered sta-
tistically significant. The final model will be evaluated by
performing a visual predictive check (VPC), and by
evaluation of other goodness of fit plots.
Statistical analysis
Using the population PK parameter estimates, a robust
preliminary dosing algorithm will then be developed
through the following design-based sequential analytical
approaches:
(a)Determination of the effect of various patient and
RRT factors on PK parameters: this analysis will
provide the effect size and significance of various
patient and RRT factors on the confidence
boundaries of individual PK parameters obtained
from basic models. This approach will provide
robust estimates of differences in average levels of
individual PK parameters by RRT modalities.
(b)Evaluation of statistical distributions of PK
parameters and determination of the optimum
antibiotic dosing limits in patients receiving different
RRT modes: this analysis will explore appropriate
models to determine the confidence boundaries of
PK parameters, CL and Vd for each antibiotic
during the different RRT modes and settings, and
will then use a simulation approach using these
basic models to define the range of appropriate
doses for the antibiotics.
(c)Development of an enhanced preliminary prediction
algorithm for antibiotic dosing: this final step will
incorporate the statistically significant and clinically
relevant predictors from step (a) into the basic
models from step (b) to attempt to develop a robust
dosing guideline for individual forms of RRT.
Sample size and power
The power analysis is aimed at establishing the confi-
dence boundaries of individual PK parameters under dif-
ferent RRT modalities and settings. For vancomycin,
piperacillin/tazobactam and meropenem, to construct a
95 % confidence boundary of clearance, with standard
deviation as high as 2.5 L/h with 80 % power, we will
need 45 samples of patient data for each particular RRT
modality. For the three modalities for these antibiotics,
we will need a minimum of 135 patients per antibiotic.
A total sample of 450 patients for the three antibiotics
(150 patients each) is required to allow for potential at-
trition. Based on pre-study survey activities linezolid is
prescribed less frequently at the study sites. Therefore,
we will construct a 95 % confidence boundary of clear-
ance, with standard deviation as high as 1.5 L/h which
requires 15 patients per antibiotic per RRT modality (45
patients per antibiotic). We will enrol at least 50 patients
for linezolid to allow for potential attrition.
Discussion
The difficulty in predicting the PK profile of ICU patients
receiving RRT lies in the physiological alterations of crit-
ical illness and the different operational characteristics of
RRT [17]. This, in turn, challenges an optimised approach
to antibiotic prescribing for these patients, with failure to
achieve optimal blood antibiotic concentrations and po-
tentially a negative impact on survival [1, 2]. The aim of
the study is to quantify the effects of critical illness and
the use of RRT on the PK parameters of five common an-
tibiotics in a large cohort of ICU patients and to attempt
to develop robust antibiotic dosing guidelines for ICU pa-
tients that account for specific patient characteristics and
the type of RRT they are prescribed.
The investigators hypothesise that the uncertainty of
the magnitude of the influence of patient and RRT fac-
tors on PK can be defined by the systematic exploration
of these factors in a large, multi-centre ICU patient co-
hort, such as that to be investigated in this study. The
first step is the recording of the detailed description of
enrolled patients’ demographic and clinical parameters,
particularly organ function (defined by components of
the Sequential Organ Failure Assessment (SOFA) score),
RRT modalities and settings, together with the plasma
antibiotic concentration-time data. This comprehensive
data set will permit the description of detailed PK data, and
allow further analysis of the effect of critical illness, AKI
and RRT on the drug disposition of five of the most com-
monly used antibiotics in ICU patients, namely, vanco-
mycin, linezolid, piperacillin/tazobactam and meropenem.
Following this, it will be possible to evaluate the statis-
tical distributions of PK parameters and determine the
optimum antibiotic dosing limits during different regi-
mens of RRT. This analysis will explore appropriate
models to determine the confidence boundaries of PK
parameters, such as Vd and CL for each antibiotic dur-
ing the different regimens of RRT, adjusted for relevant
patient characteristics. The information obtained will
then be used, via a simulation approach, in these basic
models to define the range of appropriate doses for the
studied antibiotics.
Finally, analysing the effect of various patient and RRT
factors on PK parameters should provide an estimate of
the effect size and significance of various patient and
RRT factors on the confidence boundaries of individual
PK parameters obtained from the basic models derived
earlier. This approach should provide robust estimates
of changes in individual PK parameters induced by crit-
ical illness and by different RRT modalities. In essence,
population PK modeling should allow us to quantify the
levels of variability shown in these patients, and the
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effect of each individual physiological and pathological
characteristic. In a similar way, the statistical modeling
should allow the quantification of the effects of different
modes and settings of RRT on the disposition of the
studied antibiotics.
Utilising the information developed through the above
process, we expect to be able to develop an enhanced
preliminary prediction algorithm for antibiotic dosing.
This final step will incorporate the statistically significant
and clinically relevant predictors from the above steps,
into initial basic models, thereby developing a robust
dosing guideline for commonly used forms of RRT. If
such dosing guidelines are successful, they are likely to
improve the effectiveness of the prescribed therapy
against target pathogens by ensuring clinically effective
blood concentrations of the antibiotics investigated. The
enhanced preliminary prediction algorithm may then
undergo subsequent validation by means of a large-scale
randomised control trial with mortality as a primary
outcome.
Conclusions
Current guidelines for dosing in septic critically ill pa-
tients with AKI receiving RRT are likely to be inad-
equate. The modality and operational settings of RRT
can be significantly different between different ICUs.
These different practices result in meaningfully different
antibiotic blood concentrations and as such a singular
antibiotic dose to cover all RRT scenarios is unlikely to
be effective. This study is the first multi-national obser-
vational PK study aimed at determining the important
factors that contribute to antibiotic blood concentra-
tions, attempting to generate models to predict these
changes and to utilise the models to improve clinical
guidelines. To achieve this, the PK variability of the five
antibiotics commonly used in patients with AKI who are
undergoing RRT will be investigated. Robust data from
this multi-centre cohort of patients should provide the
required PK knowledge with sufficient statistical power
to develop an enhanced algorithm for antibiotic dosing
in this specific population of critically patients.
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